Xarelto 15mg 14 tablets — Made in Germany — Free Delivery

Product description

Xarelto tablets are indicated for:

• Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation and one or more risk factors, such as congestive heart failure, arterial hypertension, age ≥ 75 years, diabetes mellitus, stroke, or a history of transient ischemic attack.
• Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrence of DVT and PE in adults.

Structure

Active substance: rivaroxaban;

1 coated tablet contains 15 mg of rivaroxaban;

1 coated tablet contains 20 mg rivaroxaban;

Excipients: microcrystalline cellulose, sodium croscarmellose, hypromellose 5 cf, hypromellose 15 cf, lactose, magnesium stearate, sodium lauryl sulfate, macrogol 3350, titanium dioxide (E 171), iron oxide red (E 172).

Contraindications

Hypersensitivity to rivaroxaban or to any excipients of the preparation.

Clinically significant active bleeding.

Injury or conditions accompanied by a significant risk of bleeding, which include currently or recently diagnosed ulcers of the gastrointestinal tract, malignant tumors with a high risk of bleeding, recent brain or spinal cord injury, recent surgery on the main, spinal cord or eyes, recent intracranial hemorrhage, esophageal varices (detected or suspected), arteriovenous malformations, vascular aneurysms, or significant intraspinal or intracerebral vascular abnormalities.

Simultaneous use with any other anticoagulants, in particular unfractionated heparin, low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexil and p. .), except for the specific circumstances of the transition to alternative anticoagulant therapy or cases when unfractionated heparin is prescribed in doses necessary for the functioning of an open catheter of the central veins or arteries.

Liver diseases associated with coagulopathy and a clinically significant risk of bleeding, including class B and C liver cirrhosis (according to the Child-Pugh classification).

The patient's age is up to 18 years.

During pregnancy and breastfeeding.

Mode of application

For oral administration.

Xarelto 15 mg and 20 mg tablets should be taken with meals.

For patients who are unable to swallow a whole tablet, it can be crushed and mixed with water or soft food, such as applesauce, just before ingestion. After prescribing Xarelto tablets 15 mg or 20 mg in a crushed state to the patient, the preparation in the indicated form must be taken in direct connection with the introduction of food.

Xarelto tablets in crushed form can be administered through a gastric tube. The correct position of the probe in the stomach should be checked before the introduction of Xarelto. Crushed tablets should be administered with a small amount of water through a gastric tube, after which the tube should be rinsed with water. After prescribing Xarelto tablets 15 mg or 20 mg in a crushed state to the patient, the preparation in the indicated form must be administered through a tube immediately after enteral nutrition.

Application features

Pregnant

Contraindicated.

Children

Contraindicated.

Drivers

Carefully.

Overdose

There have been rare cases of overdose (up to 600 mg) without complications such as bleeding or other adverse reactions. Due to limited absorption, when the preparation is administered at doses significantly higher than therapeutic doses (50 mg or higher), a satiety effect is expected without further increase in mean plasma level.

A specific neutralizing agent (andexanet alfa) that counteracts the pharmacological effects of rivaroxaban (see the Summary of Product Characteristics for andexanet alfa). In case of preparation overdose, activated charcoal can be used to reduce the absorption of rivaroxaban.

Side effects

The most common reported adverse reactions in patients receiving rivaroxaban were bleeding. There were frequent reports of nosebleeds (4.5%) and bleeding from the gastrointestinal tract (3.8%).

Interaction

Simultaneous use with any other anticoagulants, in particular unfractionated heparin, low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexil and p. .), except for the specific circumstances of the transition to alternative anticoagulant therapy or cases when unfractionated heparin is prescribed in doses necessary for the functioning of an open catheter of the central veins or arteries.

Storage conditions

Keep out of the reach of children at a temperature not exceeding 30 ° C.

Shelf life is 3 years.